OCUTF (Ocumension Therapeutics) Change In Receivables: $-25.4 Mil (TTM As of Dec. 2025)


OCUTF Ocumension Therapeutics OCUTF
52 GF Score
Price $0.70
GF Value $2.82
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Ocumension Therapeutics Change In Receivables?

Ocumension Therapeutics OCUTF 52 Change In Receivables is $-25.4 Mil as of Dec. 2025. GuruFocus rates OCUTF with a GF Score™ of 52/100 and a GF Value™ of $2.82 (Possible Value Trap). The stock has 5 warning signs investors should review.

Ocumension Therapeutics's change in receivables for the quarter that ended in Dec. 2025 was $-23.1 Mil. It means Ocumension Therapeutics's Accounts Receivable increased by $23.1 Mil from Jun. 2025 to Dec. 2025 .

Ocumension Therapeutics's change in receivables for the fiscal year that ended in Dec. 2025 was $-25.5 Mil. It means Ocumension Therapeutics's Accounts Receivable increased by $25.5 Mil from Dec. 2024 to Dec. 2025 .

Ocumension Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2025 was $48.2 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Ocumension Therapeutics's Days Sales Outstanding for the six months ended in Dec. 2025 was 121.45.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Ocumension Therapeutics's liquidation value for the six months ended in Dec. 2025 was $60.2 Mil.

Ocumension Therapeutics  (OTCPK:OCUTF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Ocumension Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=48.219/72.456*91
=121.45

2. In Ben Graham's calculation of liquidation value, Ocumension Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Ocumension Therapeutics's liquidation value for the quarter that ended in Dec. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=77.735-58.242+0.75 * 48.219+0.5 * 9.075
=60.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocumension Therapeutics Change In Receivables Related Terms

Ocumension Therapeutics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Ocumension Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocumension Therapeutics Change In Receivables Chart

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial -4.89 -4.77 -1.07 -5.35 -25.47

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.75 -3.24 -2.12 -2.35 -23.07
OCUTF
52GF Score
Ocumension Therapeutics OCUTF
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ocumension Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-25.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-25.4 Mil mean?
Ocumension Therapeutics (OCUTF) has a Change In Receivables of $-25.4 Mil as of Dec. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Ocumension Therapeutics and its competitors.
Is Ocumension Therapeutics' Change In Receivables too high?
Ocumension Therapeutics' current Change In Receivables is $-25.4 Mil. Overall, Ocumension Therapeutics has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ocumension Therapeutics' Change In Receivables compare to VRTX and REGN?
Ocumension Therapeutics' Change In Receivables of $-25.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Ocumension Therapeutics and its competitors. Ocumension Therapeutics's current Change In Receivables is $-25.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocumension Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ocumension Therapeutics (OCUTF) is currently considered Possible Value Trap. The stock's GF Value™ is $2.82, compared to a current price of $0.70 — trading 75.2% below its estimated fair value. The current Change In Receivables is $-25.4 Mil. Ocumension Therapeutics' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Ocumension Therapeutics (OCUTF), the current Change In Receivables is $-25.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ocumension Therapeutics (OCUTF) Overvalued in 2026?

Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued. The current stock price of $0.70 is trading 75.2% below its estimated GF Value™ of $2.82. GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.

Key valuation signals for OCUTF:

  • Change In Receivables: $-25.4 Mil
  • GF Value™: $2.82 vs. price of $0.70 (75.2% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the OCUTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ocumension Therapeutics Business Description

Other Exchanges 01477:Hong Kong5DG:Germany
Address No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
52GF Score

Get the complete analysis for OCUTF

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price
$2.82
GF Value